OpenURL Connection Search

Select item for more details and to access through your institution.

Zellzahl und Entzündungsparameter im peripheren Blut bei chronischer Rhinosinusitis.
Published in:
HNO, 2018, v. 66, n. 8, p. 605, doi. 10.1007/s00106-018-0527-0
By:
- Zagólski, O.;
- Stręk, P.;
- Jurczak, W.;
- Gorzedowski, P.
Publication type:
Article
Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network.
Published in:
2011
By:
- Hohloch, K.;
- Zinzani, P. L.;
- Linkesch, W.;
- Jurczak, W.;
- Deptala, A.;
- Lorsbach, M.;
- Windemuth-Kiesselbach, C.;
- Wulf, G. G.;
- Truemper, L .H.
Publication type:
Letter
SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: LONGER FOLLOW‐UP FROM THE PIVOTAL EPCORE NHL‐1 TRIAL.
Published in:
Hematological Oncology, 2023, v. 41, p. 142, doi. 10.1002/hon.3163_94
By:
- Thieblemont, C.;
- Karimi, Y.;
- Jurczak, W.;
- Cheah, C. Y.;
- Clausen, M. R.;
- Cunningham, D.;
- Do, Y. R.;
- Lewis, D. J.;
- Gasiorowski, R.;
- Kim, T. M.;
- van der Poel, M.;
- Poon, M. L.;
- Feldman, T.;
- Linton, K. M.;
- Sureda, A.;
- Hutchings, M.;
- Cottereau, A.;
- Al Tabaa, Y.;
- Stirner, M. Cota;
- Liu, Y.
Publication type:
Article
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
Published in:
Hematological Oncology, 2023, v. 41, p. 129, doi. 10.1002/hon.3163_87
By:
- Danilov, A.;
- Gregory, G. P.;
- Morschhauser, F.;
- Cheah, C. Y.;
- Shah, H.;
- Jurczak, W.;
- Olabode, D.;
- Meyer, S.;
- Yoon, J. L.;
- Arduini, S.;
- Saeh, J.;
- Olsson, R. F.;
- Strati, P.
Publication type:
Article
COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS.
Published in:
Hematological Oncology, 2023, v. 41, p. 758, doi. 10.1002/hon.3165_605
By:
- Jurczak, W.;
- Lamanna, N.;
- Tam, C. S.;
- Kontos, A.;
- Konig, H.;
- Ruppert, A. S.;
- Tsai, D. E.
Publication type:
Article
Safety and Efficacy of Acalabrutinib, Bendamustine, and Rituximab in Patients with Treatment‐Naive or Relapsed/Refractory Mantle Cell Lymphoma: Phase Ib Trial.
Published in:
Hematological Oncology, 2023, v. 41, p. 586, doi. 10.1002/hon.3164_439
By:
- Phillips, T.;
- Wang, M.;
- Robak, T.;
- Gallinson, D.;
- Stevens, D.;
- Patel, K.;
- Ramadan, S.;
- Wun, C.;
- Jurczak, W.;
- Smith, S. D.
Publication type:
Article
CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study.
Published in:
Hematological Oncology, 2023, v. 41, p. 584, doi. 10.1002/hon.3164_438
By:
- Munoz, J.;
- Hoffmann, M.;
- Westin, J.;
- Vassilakopoulos, T. P.;
- García‐Sancho, A. M.;
- Rueda‐Domínguez, A.;
- Jurczak, W.;
- Kwiatek, M.;
- Bouzani, M.;
- Gkasiamis, A.;
- Patel, A.;
- Boucaud, F.;
- Li, J.;
- Nowakowski, G. S.
Publication type:
Article
Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).
Published in:
Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
By:
- McDonald, A.;
- Verburgh, E.;
- Gotti, M.;
- Pinto, A.;
- Zaucha, J.;
- Ivanov, V.;
- Melnichenko, V.;
- Mocikova, H.;
- Ozcan, M.;
- Patti, C.;
- Farias, J.;
- Goncalves, I.;
- Kuchkova, O.;
- Mayer, J.;
- Saydam, G.;
- Tomassetti, S.;
- Pathiraja, K.;
- Ryland, K.;
- Chakraborty, S.;
- Jurczak, W.
Publication type:
Article
A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006.
Published in:
Hematological Oncology, 2023, v. 41, p. 564, doi. 10.1002/hon.3164_422
By:
- Zinzani, P. L.;
- Mayer, J.;
- Benjamini, O.;
- Berkovits, A.;
- Glimelius, I.;
- Stevens, D.;
- Chaudhry, A.;
- Demir, A. M.;
- Sanz, R. G.;
- Kim, W. S.;
- Li, F.;
- Halka, J.;
- Marin‐Niebla, A.;
- Ozcan, M.;
- Paszkiewicz‐Kozik, E.;
- Santoro, A.;
- Ren, Y.;
- Ogbu, U.;
- Marinello, P.;
- Jurczak, W.
Publication type:
Article
Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies.
Published in:
Hematological Oncology, 2023, v. 41, p. 480, doi. 10.1002/hon.3164_353
By:
- Wang, Y.;
- Coombs, C. C.;
- Shah, N. N.;
- Jurczak, W.;
- Woyach, J.;
- Cheah, C. Y.;
- Patel, K.;
- Maddocks, K.;
- Muehlenbein, C. E.;
- Wang, C.;
- Abhyankar, S.;
- Tsai, D. E.;
- Eyre, T. A.
Publication type:
Article
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database.
Published in:
Hematological Oncology, 2023, v. 41, p. 459, doi. 10.1002/hon.3164_339
By:
- Brown, J. R.;
- Eichorst, B.;
- Ghia, P.;
- Jurczak, W.;
- Kahl, B. S.;
- Lamanna, N.;
- Robak, T.;
- Shadman, M.;
- Tam, C. S.;
- Qiu, L.;
- Cohen, A.;
- Zhang, M.;
- Salmi, T.;
- Paik, J.;
- Wang, L.;
- Zhang, J.;
- Ma, H.;
- Tedeschi, A.
Publication type:
Article
Five‐year subgroup analysis of tafasitamab + lenalidomide from the Phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2023, v. 41, p. 439, doi. 10.1002/hon.3164_324
By:
- Duell, J.;
- Abrisqueta, P.;
- Dreyling, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study.
Published in:
Hematological Oncology, 2023, v. 41, p. 437, doi. 10.1002/hon.3164_323
By:
- Duell, J.;
- Abrisqueta, P.;
- Andre, M.;
- Augustin, M.;
- Gaidano, G.;
- Barca, E. G.;
- Jurczak, W.;
- Kalakonda, N.;
- Liberati, A. M.;
- Maddocks, K. J.;
- Menne, T.;
- Nagy, Z.;
- Tournilhac, O.;
- Bakuli, A.;
- Amin, A.;
- Gurbanov, K.;
- Salles, G.
Publication type:
Article
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C).
Published in:
Hematological Oncology, 2023, v. 41, p. 353, doi. 10.1002/hon.3164_254
By:
- Abramson, J. S.;
- Straus, D.;
- Bartlett, N.;
- Burke, J. M.;
- Lynch, R. C.;
- Domingo‐Domenech, E.;
- Hess, B.;
- Schuster, S.;
- Linhares, Y.;
- Ramchandren, R.;
- Gandhi, M.;
- Mowat, R.;
- Shah, H.;
- Jurczak, W.;
- Re, A.;
- Hahn, U.;
- Prince, H. M.;
- Ho, L.;
- Guo, W.;
- Jain, S.
Publication type:
Article
Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia (CLL) From a Head‐to‐Head Trial of Acalabrutinib Versus Ibrutinib.
Published in:
Hematological Oncology, 2023, v. 41, p. 249, doi. 10.1002/hon.3164_163
By:
- Woyach, J. A.;
- Jones, D.;
- Jurczak, W.;
- Robak, T.;
- Illés, A.;
- Kater, A. P.;
- Ghia, P.;
- Byrd, J. C.;
- Seymour, J. F.;
- Long, S.;
- Mohamed, N.;
- De Jesus, G.;
- Lai, R.;
- de Bruin, G.;
- Butturini, A.;
- Rule, S.;
- Munugalavadla, V.
Publication type:
Article
GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 185, doi. 10.1002/hon.3163_116
By:
- Patel, K.;
- Brown, J. R.;
- Desikan, S. P.;
- Nguyen, B.;
- Won, H.;
- Tantawy, S. I.;
- McNeely, S. C.;
- Marella, N.;
- Ebata, K.;
- Woyach, J. A.;
- Tam, C. S.;
- Eyre, T. A.;
- Cheah, C. Y.;
- Shah, N. N.;
- Ghia, P.;
- Jurczak, W.;
- Balbas, M.;
- Nair, B.;
- Abada, P.;
- Wang, C.
Publication type:
Article
PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT.
Published in:
Hematological Oncology, 2023, v. 41, p. 153, doi. 10.1002/hon.3163_102
By:
- Cheah, C. Y.;
- Shah, N. N.;
- Jurczak, W.;
- Zinzani, P. Luigi;
- Eyre, T. A.;
- Ujjani, C. S.;
- Izutsu, K.;
- Ma, S.;
- Flinn, I.;
- Alencar, A. J.;
- Lewis, D.;
- Patel, K.;
- Maddocks, K.;
- Wang, Y.;
- Munir, T.;
- Zelenetz, A. D.;
- Balbas, M.;
- Tsai, D. E.;
- Wang, C.;
- Wang, M. L.
Publication type:
Article
PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.41_2880
By:
- Jurczak, W.;
- Shah, N. N.;
- Lamanna, N.;
- Eyre, T. A.;
- Woyach, J.;
- Lech‐Maranda, E.;
- Wierda, W. G.;
- Lewis, D.;
- Thompson, M. C.;
- Wang, D.;
- Yin, M.;
- Balbas, M.;
- Nair, B. C.;
- Zhu, E. Y.;
- Tsai, D. E.;
- Ku, N. C.;
- Coombs, C. C.;
- Mato, A. R.
Publication type:
Article
LONG‐TERM ANALYSES FROM L‐MIND, A PHASE II STUDY OF TAFASITAMAB PLUS LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.28_2879
By:
- Duell, J;
- Maddocks, K. J;
- González‐Barca, E;
- Jurczak, W;
- Liberati, A. M;
- Obr, A;
- Gaidano, G;
- Abrisqueta, P;
- André, M;
- Dreyling, M;
- Menne, T;
- Dirnberger‐Hertweck, M.;
- Weirather, J;
- Ambarkhane, S;
- Salles, G
Publication type:
Article
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.21_2880
By:
- Batlevi, C. L.;
- Salles, G.;
- Tilly, H.;
- Chaidos, A.;
- McKay, P.;
- Phillips, T.;
- Assouline, S.;
- Campbell, P.;
- Ribrag, V.;
- Damaj, G. Laurent;
- Dickinson, M.;
- Jurczak, W.;
- Kaźmierczak, M.;
- Opat, S.;
- Radford, J. R.;
- Schmitt, A.;
- Rajarethinam, A.;
- Shang, G.;
- Morschhauser, F.
Publication type:
Article
CHRONOS‐3: RANDOMIZED PHASE III STUDY OF COPANLISIB PLUS RITUXIMAB VS RITUXIMAB/PLACEBO IN RELAPSED INDOLENT NON‐HODGKIN LYMPHOMA (INHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.24_2880
By:
- Zinzani, P. L.;
- Capra, M.;
- Özcan, M.;
- Lv, F.;
- Li, W.;
- Yañez, E.;
- Sapunarova, K.;
- Lin, T.;
- Jin, J.;
- Jurczak, W.;
- Hamed, A.;
- Wang, M.‐C.;
- Baker, R.;
- Bondarenko, I.;
- Zhang, Q.;
- Feng, J.;
- Geissler, K.;
- Lazaroiu, M.;
- Saydam, G.;
- Szomor, Á.
Publication type:
Article
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.174_2880
By:
- Jurczak, W.;
- Zinzani, P. L.;
- Cunningham, D.;
- Yavrom, S.;
- Huang, W.;
- Gorbatchevsky, I.;
- Ribrag, V.
Publication type:
Article
FIRST‐LINE IBRUTINIB + VENETOCLAX TREATMENT FOR MANTLE CELL LYMPHOMA IN OLDER PATIENTS OR THOSE WITH TP53 MUTATION: A NEW OPEN‐LABEL ARM OF THE PHASE 3 PCYC‐1143 SYMPATICO STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.172_2880
By:
- Jurczak, W.;
- Tam, C.;
- Eckert, K.;
- Lin, J.;
- Neuenburg, J. K.;
- Wang, M. L.
Publication type:
Article
SAFETY AND EFFICACY OF CD37‐TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B‐CELL LYMPHOMA AND OTHER NON‐HODGKIN’S B‐CELL LYMPHOMAS – A PHASE 2 STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.156_2880
By:
- Levy, M. Y.;
- Grudeva‐Popova, Z.;
- Trneny, M.;
- Jurczak, W.;
- Pylypenko, H.;
- Jagadeesh, D.;
- Andre, M.;
- Nasta, S.;
- Rechavi‐Robinson, D.;
- Toffanin, S.;
- Micallef, S.;
- Attinger, A.;
- Rouits, E.;
- Dymkowska, M.;
- Nauwelaerts, H.;
- Woei‐A‐Jin, F. J. S. H.
Publication type:
Article
MOSUNETUZUMAB MONOTHERAPY IN ELDERLY/UNFIT PTS WITH FIRST‐LINE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): SAFETY AND EFFICACY REMAIN PROMISING WITH DURABLE COMPLETE RESPONSES.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.152_2880
By:
- Olszewski, A. J;
- Avigdor, A;
- Babu, S;
- Levi, I;
- Eradat, H;
- Abadi, U;
- Holmes, H;
- McKinney, M;
- Woszczyk, D;
- Giannopoulos, K;
- Jurczak, W;
- McCord, R;
- Xie, Y;
- Sarouei, K;
- Qayum, N;
- O'Hear, C;
- Sellam, G;
- Horowitz, N
Publication type:
Article
TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.148_2880
By:
- Cheah, C. Y;
- Jurczak, W;
- Lasica, M;
- Wickham, N;
- Wróbel, T;
- Walewski, J;
- Yannakou, C. K;
- Cheung, S;
- Lewis, K. L;
- Długosz‐Danecka, M;
- Giannopoulos, K;
- Miskin, H. P;
- Tang, J.‐P;
- Normant, E;
- O'Connor, O. A;
- Ricart, A. D;
- Tam, C. S
Publication type:
Article
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
Published in:
Hematological Oncology, 2019, v. 37, p. 86, doi. 10.1002/hon.54_2629
By:
- Ghia, P.;
- Pluta, A.;
- Wach, M.;
- Lysak, D.;
- Kozak, T.;
- Simkovic, M.;
- Kaplan, P.;
- Kraychok, I.;
- Illes, A.;
- De La Serna, J.;
- Dolan, S.;
- Campbell, P.;
- Musuraca, G.;
- Jacob, A.;
- Avery, E.J.;
- Lee, J.H.;
- Chen, T.;
- Liang, W.;
- Patel, P.;
- Jurczak, W.
Publication type:
Article
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
By:
- Vitolo, U.;
- Witzig, T.E.;
- Gascoyne, R.D.;
- Scott, D.W.;
- Zhang, Q.;
- Jurczak, W.;
- Özcan, M.;
- Hong, X.;
- Zhu, J.;
- Jin, J.;
- Belada, D.;
- Bergua, J.M.;
- Piazza, F.;
- Mócikova, H.;
- Molinari, A.L.;
- Yoon, D.H.;
- Cavallo, F.;
- Tani, M.;
- Izutsu, K.;
- Kato, K.
Publication type:
Article
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 554, doi. 10.1002/hon.2632
By:
- Wang, M.;
- Belada, D.;
- Cheah, C.;
- Chu, M.P.;
- Dreyling, M.;
- Flinn, I.;
- Fogliatto, L.;
- Goy, A.;
- Inwards, D.;
- Jurczak, W.;
- Mayer, J.;
- Re, F.;
- Robak, T.;
- Spurgeon, S.;
- Yoon, S.S.;
- Zinzani, P.L.;
- Yin, M.;
- Chen, T.;
- Kahl, B.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 333, doi. 10.1002/hon.146_2630
By:
- Wang, M.;
- Ramchandren, R.;
- Chen, R.;
- Karlin, L.;
- Chong, G.;
- Jurczak, W.;
- Wu, K.;
- Bishton, M.;
- Collins, G.;
- Eliadis, P.;
- Peyrade, F.;
- Freise, K.;
- Sukbuntherng, J.;
- Lee, Y.;
- Dobkowska, E.;
- Fedorov, V.;
- Neuenburg, J.;
- Tam, C.
Publication type:
Article
UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 182, doi. 10.1002/hon.139_2629
By:
- Zinzani, P.;
- Samaniego, F.;
- Jurczak, W.;
- Lech‐Maranda, E.;
- Ghosh, N.;
- Anz, B.;
- Patten, P.;
- Reeves, J.;
- Leslie, L.A.;
- Smolewski, P.;
- Chavez, J.C.;
- Scarfo, L.;
- Derenzini, E.;
- Burke, J.M.;
- Sharman, J.;
- Kolibaba, K.;
- O'Connor, O.A.;
- Cheah, C.Y.;
- Miskin, H.P.;
- Sportelli, P.
Publication type:
Article
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND).
Published in:
Hematological Oncology, 2019, v. 37, p. 173, doi. 10.1002/hon.130_2629
By:
- Salles, G.;
- Duell, J.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Nagy, Z.;
- Obr, A.;
- Gaidano, G.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Dirnberger‐Hertweck, M.;
- Weirather, J.;
- Ambarkhane, S.;
- Maddocks, K.
Publication type:
Article
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 154, doi. 10.1002/hon.111_2629
By:
- Morschhauser, F.;
- Tilly, H.;
- Chaidos, A.;
- Phillips, T.;
- Ribrag, V.;
- Campbell, P.;
- Ghandi Laurent, D.;
- Jurczak, W.;
- McKay, P.;
- Opat, S.;
- Radford, J.;
- Rajarethinam, A.;
- Yang, J.;
- Howell, H.;
- Newberry, K.J.;
- Adib, D.;
- Salles, G.
Publication type:
Article
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study.
Published in:
Hematological Oncology, 2019, v. 37, p. 86, doi. 10.1002/hon.54_2629
By:
- Ghia, P.;
- Pluta, A.;
- Wach, M.;
- Lysak, D.;
- Kozak, T.;
- Simkovic, M.;
- Kaplan, P.;
- Kraychok, I.;
- Illes, A.;
- De La Serna, J.;
- Dolan, S.;
- Campbell, P.;
- Musuraca, G.;
- Jacob, A.;
- Avery, E.J.;
- Lee, J.H.;
- Chen, T.;
- Liang, W.;
- Patel, P.;
- Jurczak, W.
Publication type:
Article
ROBUST: First report of phase III randomized study of lenalidomide/R‐CHOP (R2‐CHOP) vs placebo/R‐CHOP in previously untreated ABC‐type diffuse large B‐cell lymphoma.
Published in:
Hematological Oncology, 2019, v. 37, p. 36, doi. 10.1002/hon.5_2629
By:
- Vitolo, U.;
- Witzig, T.E.;
- Gascoyne, R.D.;
- Scott, D.W.;
- Zhang, Q.;
- Jurczak, W.;
- Özcan, M.;
- Hong, X.;
- Zhu, J.;
- Jin, J.;
- Belada, D.;
- Bergua, J.M.;
- Piazza, F.;
- Mócikova, H.;
- Molinari, A.L.;
- Yoon, D.H.;
- Cavallo, F.;
- Tani, M.;
- Izutsu, K.;
- Kato, K.
Publication type:
Article
A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 554, doi. 10.1002/hon.2632
By:
- Wang, M.;
- Belada, D.;
- Cheah, C.;
- Chu, M.P.;
- Dreyling, M.;
- Flinn, I.;
- Fogliatto, L.;
- Goy, A.;
- Inwards, D.;
- Jurczak, W.;
- Mayer, J.;
- Re, F.;
- Robak, T.;
- Spurgeon, S.;
- Yoon, S.S.;
- Zinzani, P.L.;
- Yin, M.;
- Chen, T.;
- Kahl, B.
Publication type:
Article
UMBRALISIB MONOTHERAPY DEMONSTRATES EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A MULTICENTER, OPEN‐LABEL, REGISTRATION DIRECTED PHASE 2 STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 182, doi. 10.1002/hon.139_2629
By:
- Zinzani, P.;
- Samaniego, F.;
- Jurczak, W.;
- Lech‐Maranda, E.;
- Ghosh, N.;
- Anz, B.;
- Patten, P.;
- Reeves, J.;
- Leslie, L.A.;
- Smolewski, P.;
- Chavez, J.C.;
- Scarfo, L.;
- Derenzini, E.;
- Burke, J.M.;
- Sharman, J.;
- Kolibaba, K.;
- O'Connor, O.A.;
- Cheah, C.Y.;
- Miskin, H.P.;
- Sportelli, P.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 333, doi. 10.1002/hon.146_2630
By:
- Wang, M.;
- Ramchandren, R.;
- Chen, R.;
- Karlin, L.;
- Chong, G.;
- Jurczak, W.;
- Wu, K.;
- Bishton, M.;
- Collins, G.;
- Eliadis, P.;
- Peyrade, F.;
- Freise, K.;
- Sukbuntherng, J.;
- Lee, Y.;
- Dobkowska, E.;
- Fedorov, V.;
- Neuenburg, J.;
- Tam, C.
Publication type:
Article
PRIMARY ANALYSIS RESULTS OF THE SINGLE‐ARM PHASE II STUDY OF MOR208 PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (L‐MIND).
Published in:
Hematological Oncology, 2019, v. 37, p. 173, doi. 10.1002/hon.130_2629
By:
- Salles, G.;
- Duell, J.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Nagy, Z.;
- Obr, A.;
- Gaidano, G.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Dirnberger‐Hertweck, M.;
- Weirather, J.;
- Ambarkhane, S.;
- Maddocks, K.
Publication type:
Article
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 154, doi. 10.1002/hon.111_2629
By:
- Morschhauser, F.;
- Tilly, H.;
- Chaidos, A.;
- Phillips, T.;
- Ribrag, V.;
- Campbell, P.;
- Ghandi Laurent, D.;
- Jurczak, W.;
- McKay, P.;
- Opat, S.;
- Radford, J.;
- Rajarethinam, A.;
- Yang, J.;
- Howell, H.;
- Newberry, K.J.;
- Adib, D.;
- Salles, G.
Publication type:
Article
IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 143, doi. 10.1002/hon.2437_133
By:
- Rule, S.;
- Jurczak, W.;
- Jerkeman, M.;
- Santucci Silva, R.;
- Rusconi, C.;
- Trneny, M.;
- Offner, F.;
- Caballero, D.;
- Joao, C.;
- Witzens ‐ Harig, M.;
- Hess, G.;
- Bence ‐ Bruckler, I.;
- Cho, S.;
- Thieblemont, C.;
- Zhou, W.;
- Henninger, T.;
- Goldberg, J.D.;
- Vermeulen, J.;
- Dreyling, M.
Publication type:
Article
Radioimmunotherapy for follicular lymphoma achieves excellent lymphoma control in first line and relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
Published in:
Hematological Oncology, 2017, v. 35, p. 361, doi. 10.1002/hon.2439_116
By:
- Hohloch, K.;
- Scholz, C.;
- Windemuth ‐ Kiesselbach, C.;
- Kolz, J.;
- Zinzani, P.L.;
- Cacchione, R.;
- Woijciech Jurczak, W.;
- Bischof ‐ Delalaoye, A.;
- Truemper, L.
Publication type:
Article
A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 218, doi. 10.1002/hon.2438_83
By:
- Buske, C.;
- Kim, W.;
- Kwak, L.;
- Coiffier, B.;
- Jurczak, W.;
- Sancho, J.M.;
- Zhavrid, E.;
- Kim, J.;
- Hernández Rivas, J.Á.;
- Prokharau, A.;
- Vasilica, M.;
- Nagarkar, R.;
- Osmanov, D.;
- Lee, S.;
- Bae, Y.;
- Ogura, M.
Publication type:
Article
Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study.
Published in:
Hematological Oncology, 2017, v. 35, p. 210, doi. 10.1002/hon.2438_75
By:
- Fowler, N.;
- Gopal, A.K.;
- Schuster, S.J.;
- Trotman, J.;
- Hess, G.;
- Hou, J.;
- Yacoub, A.;
- Lill, M.;
- Martin, P.;
- Vitolo, U.;
- Spencer, A.;
- Radford, J.;
- Jurczak, W.;
- Morton, J.;
- Osmanov, D.;
- Caballero, D.;
- Deshpande, S.;
- Vermeulen, J.;
- Damle, R.;
- Schaffer, M.
Publication type:
Article
LYMRIT 37-01: UPDATED RESULTS OF A PHASE I/II STUDY OF 177LU-LILOTOMAB SATETRAXETAN, A NOVEL CD37-TARGETED ANTIBODY- RADIONUCLIDE-CONJUGATE IN RELAPSED NHL PATIENTS.
Published in:
Hematological Oncology, 2017, v. 35, p. 269, doi. 10.1002/hon.2438_142
By:
- Kolstad, A.;
- Madsbu, U.;
- Beasley, M.;
- Bayne, M.;
- Illidge, T.;
- O'Rourke, N.;
- Lagerlöf, I.;
- Hájek, R.;
- Jurczak, W.;
- Willenbacher, E.;
- Blakkisrud, J.;
- Muftuler Løndalen, A.;
- Rojkjaer, L.;
- Baylor Curtis, L.;
- Bloma, M.;
- Turner, S.;
- Bolstad, N.;
- Spetalen, S.;
- Erlanson, M.;
- Nygaard, S.
Publication type:
Article
L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) - A SINGLE-ARM PHASE II STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 51, doi. 10.1002/hon.2437_35
By:
- Salles, G.;
- González Barca, E.;
- Jurczak, W.;
- Liberati, A.M.;
- Duell, J.;
- Nagy, Z.;
- Papajík, T.;
- Andre, M.;
- Kalakonda, N.;
- Dreyling, M.;
- Zinzani, P.L.;
- Ambarkhane, S.;
- Weirather, J.;
- Maddocks, K.
Publication type:
Article
INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS.
Published in:
Hematological Oncology, 2017, v. 35, p. 24, doi. 10.1002/hon.2437_3
By:
- Morschhauser, F.;
- Salles, G.;
- McKay, P.;
- Tilly, H.;
- Schmitt, A.;
- Gerecitano, J.;
- Johnson, P.;
- Le Gouill, S.;
- Dickinson, M.J.;
- Fruchart, C.;
- Lamy, T.;
- Chaidos, A.;
- Jurczak, W.;
- Opat, S.;
- Radford, J.;
- Zinzani, P.L.;
- Assouline, S.;
- Cartron, G.;
- Clawson, A.;
- Picazio, N.
Publication type:
Article

Found: 49